This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The FDA approved BridgeBio s first drug, for a disease that affects 100 children in the US and Europe.
BridgeBio mitigates risk with a hub-and-spoke model, with a central management team and subsidiaries.
The model is gaining in popularity in biopharma and could reshape drug R&D, McKinsey & Co. says.
It wasn t that long ago that the idea behind BridgeBio drew laughter from biotech and finance experts.
But these days, CEO Neil Kumar says he s taking calls from industry insiders interested in launching companies emulating the BridgeBio model. If it helps patients, he s willing to guide rivals.
America s biggest retail chains have been pushing into healthcare with mixed results.
The pandemic has cemented the shift into healthcare for some retailers, while others have slowed their efforts.
Here s how healthcare strategies from CVS Health, Walgreens, Walmart, and Kroger have played out.
The pandemic is redefining what what health and wellness means for Americans.
After nearly a year of extended isolation and more than 500,000 deaths from COVID-19, many corporate retailers have seen their attempts to take on the $3.8 trillion healthcare industry go sideways.
During the pandemic, established industry leaders have struggled to adapt, while newcomers hoping to get a piece of the pie had their hopes dashed by shifted priorities. In February, a preliminary analysis from the nonprofit Altarum estimated that in 2020, US healthcare spending may decline for the first time in 60 years.
Brian Madeux, 44, looks up at nurse practitioner Jacqueline Madde while receiving the first human gene editing therapy at the UCSF Benioff Children s Hospital. Madeux, who has a metabolic disease called Hunter syndrome, will receive billions of copies of a corrective gene. Eric Risberg/AP This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Gene therapies, in which healthy genes are inserted into a person s system, are a booming biotech investment area.
Audentes, Bluebird bio, Sarepta, and UniQure have all run into potential safety issues in the last year.
That could spur a wave of dealmaking focused on making gene therapies safer and easier to deliver, analysts say.
Cityblock Health This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Healthcare startups trying to change the way we pay for care raised a record $3.6 billion last year.
Their progress has been limited for a decade, but changes in tech are capturing investors attention.
A CB Insights report detailed the top eight VC firms that are backing these startups.
A new kind of healthcare is gaining traction among venture capitalists.
Called value-based care, it s an approach where providers are paid based on the quality of patients health outcomes rather than how many procedures and surgeries they perform.
Roberto Machado Noa/LightRocket via Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Comcast Ventures was the independent venture arm of media giant Comcast.
In November, Comcast moved Comcast Ventures into its business development division.
It was a kingmaker of healthcare benefits startups in the past but may not be as active going forward.
To understand the rise of Comcast Ventures, the venture arm of the media and telecommunications giant, it s helpful to consider the story of a healthcare startup called Accolade.
In 2009, Accolade was trying to sign its first large client. The young company had caught the attention of Bill Strahan, then the head of global benefits at Comcast.